JP2019515653A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515653A5 JP2019515653A5 JP2018548713A JP2018548713A JP2019515653A5 JP 2019515653 A5 JP2019515653 A5 JP 2019515653A5 JP 2018548713 A JP2018548713 A JP 2018548713A JP 2018548713 A JP2018548713 A JP 2018548713A JP 2019515653 A5 JP2019515653 A5 JP 2019515653A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cancer
- cell
- variant
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 43
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 21
- 108091008874 T cell receptors Proteins 0.000 claims 20
- 210000001744 T-lymphocyte Anatomy 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 15
- 102000039446 nucleic acids Human genes 0.000 claims 15
- 150000007523 nucleic acids Chemical class 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 14
- 239000013604 expression vector Substances 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 108010028930 invariant chain Proteins 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 101000662909 Homo sapiens T cell receptor beta constant 1 Proteins 0.000 claims 1
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100037272 T cell receptor beta constant 1 Human genes 0.000 claims 1
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003139 biocide Substances 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 230000022534 cell killing Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 230000005934 immune activation Effects 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000001581 salivary duct Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022096002A JP2022130472A (ja) | 2016-03-16 | 2022-06-14 | がんに対する免疫療法で使用されるペプチドおよびペプチドの組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309107P | 2016-03-16 | 2016-03-16 | |
| US62/309,107 | 2016-03-16 | ||
| GB1604490.1 | 2016-03-16 | ||
| GBGB1604490.1A GB201604490D0 (en) | 2016-03-16 | 2016-03-16 | Peptides combination of peptides for use in immunotherapy against cancers |
| PCT/EP2017/055973 WO2017157928A1 (en) | 2016-03-16 | 2017-03-14 | Peptides and combination of peptides for use in immunotherapy against cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096002A Division JP2022130472A (ja) | 2016-03-16 | 2022-06-14 | がんに対する免疫療法で使用されるペプチドおよびペプチドの組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019515653A JP2019515653A (ja) | 2019-06-13 |
| JP2019515653A5 true JP2019515653A5 (OSRAM) | 2020-04-23 |
Family
ID=55952415
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548713A Pending JP2019515653A (ja) | 2016-03-16 | 2017-03-14 | がんに対する免疫療法で使用されるペプチドおよびペプチドの組み合わせ |
| JP2022096002A Pending JP2022130472A (ja) | 2016-03-16 | 2022-06-14 | がんに対する免疫療法で使用されるペプチドおよびペプチドの組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096002A Pending JP2022130472A (ja) | 2016-03-16 | 2022-06-14 | がんに対する免疫療法で使用されるペプチドおよびペプチドの組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10512679B2 (OSRAM) |
| EP (1) | EP3429617A1 (OSRAM) |
| JP (2) | JP2019515653A (OSRAM) |
| KR (2) | KR20180127642A (OSRAM) |
| CN (1) | CN108883165A (OSRAM) |
| AU (2) | AU2017234174B2 (OSRAM) |
| BR (1) | BR112018068489A2 (OSRAM) |
| CA (1) | CA3017652A1 (OSRAM) |
| GB (1) | GB201604490D0 (OSRAM) |
| IL (1) | IL261786A (OSRAM) |
| MX (1) | MX2018011220A (OSRAM) |
| WO (1) | WO2017157928A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| EP3635410A4 (en) * | 2017-06-04 | 2021-03-10 | Rappaport Family Institute for Research in the Medical Sciences | PROCEDURE FOR PREDICTING PERSONALIZED RESPONSE TO CANCER TREATMENT USING IMMUNE CHECKPOINT INHIBITORS AND KITS |
| CN109584966B (zh) * | 2019-01-08 | 2019-09-20 | 杭州纽安津生物科技有限公司 | 一种肿瘤通用疫苗的设计方法及胰腺癌通用疫苗 |
| DE102019114735A1 (de) * | 2019-06-02 | 2020-12-03 | PMCR GmbH | HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen |
| WO2020257922A1 (en) * | 2019-06-25 | 2020-12-30 | Université de Montréal | Novel tumor-specific antigens for ovarian cancer and uses thereof |
| CN112521484A (zh) * | 2020-12-03 | 2021-03-19 | 佛山市第一人民医院（中山大学附属佛山医院） | 结肠癌肿瘤特异tcr序列及其应用 |
| CN114133432B (zh) * | 2021-11-01 | 2023-06-16 | 暨南大学 | 一种抑制肿瘤细胞生长和转移的靶向肽及其应用 |
| CN116514909B (zh) * | 2022-08-16 | 2024-06-18 | 河南科技大学 | 一种抗肿瘤活性多肽及其制备方法与应用 |
| CN115490754B (zh) * | 2022-10-13 | 2024-04-26 | 河南科技大学 | 一种抗肿瘤活性多肽衍生物及其制备方法与应用 |
| CN117192115A (zh) * | 2023-11-03 | 2023-12-08 | 赛德特(北京)生物工程有限公司 | 检测t淋巴细胞免疫活性的方法 |
| CN117552115B (zh) * | 2024-01-12 | 2024-03-26 | 天津鲸鹏生物科技有限责任公司 | 用于诱导肿瘤特异性免疫响应的通用型抗原肽库及其应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030138438A1 (en) | 1998-03-18 | 2003-07-24 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030236209A1 (en) | 1998-03-18 | 2003-12-25 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| EP1317275A1 (de) | 2000-09-06 | 2003-06-11 | Müller, Friederike | Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| PL2113253T3 (pl) | 2008-04-30 | 2010-09-30 | Immatics Biotechnologies Gmbh | Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionce |
| US20100037514A1 (en) | 2008-05-13 | 2010-02-18 | Afton Chemical Corporation | Fuel additives to maintain optimum injector performance |
| HUE024541T2 (hu) * | 2008-05-14 | 2016-01-28 | Immatics Biotechnologies Gmbh | Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek |
| PL2172211T3 (pl) * | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| US8253536B2 (en) | 2009-04-22 | 2012-08-28 | Simon Fraser University | Security document with electroactive polymer power source and nano-optical display |
| TW201124530A (en) * | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| WO2011116126A2 (en) | 2010-03-16 | 2011-09-22 | Adapta Medical, Inc. | Catheter reservoir seals |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201015765D0 (en) | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| NZ609338A (en) | 2010-10-25 | 2015-01-30 | Stepan Co | Laundry detergents based on compositions derived from natural oil metathesis |
| GB201021289D0 (en) | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| DK2663580T3 (en) | 2011-01-10 | 2017-03-13 | Ct Atlantic Ltd | COMBINATION THERAPY INCLUDING TUMOR ASSOCIATED ANTI-BINDING ANTIBODIES |
| US10279018B2 (en) | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
| CA2893918C (en) | 2012-12-06 | 2020-11-24 | Callaghan Innovation Research Limited | Conjugate compounds |
| ES2897579T3 (es) | 2013-06-10 | 2022-03-01 | Dana Farber Cancer Inst Inc | Métodos y composiciones para reducir la inmunosupresión por células tumorales |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| MX375123B (es) | 2014-02-14 | 2025-03-06 | Immune Design Corp | Composición para usarse en mejorar la respuesta inmune contra el cáncer. |
| EP3320916B1 (en) | 2014-03-17 | 2021-09-15 | BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response |
| JP2015227292A (ja) | 2014-05-30 | 2015-12-17 | 国立大学法人高知大学 | 膵がん細胞浸潤転移抑制ワクチン |
| US10046046B2 (en) | 2014-06-05 | 2018-08-14 | Victoria Link Limited | Amino sphingoglycolipid analogues |
| GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| RS64397B1 (sr) * | 2015-03-27 | 2023-08-31 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raznih tumora (seq id 25 - mrax5-003) |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) * | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| KR20240161207A (ko) * | 2015-05-06 | 2024-11-12 | 이매틱스 바이오테크놀로지스 게엠베하 | 결장직장 암종(crc) 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드와 이의 골격의 조합 |
| TWI747524B (zh) * | 2015-06-19 | 2021-11-21 | 德商英麥提克生物技術股份有限公司 | 用於免疫治療的新穎胜肽及胜肽組合物與產生用於抗胰臟癌及其他癌症的支架的方法 |
| GB201510771D0 (en) * | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| EP3919507A3 (en) * | 2015-07-01 | 2022-01-12 | Immatics Biotechnologies GmbH | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511546D0 (en) * | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201521746D0 (en) * | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| RS63727B1 (sr) * | 2016-03-16 | 2022-12-30 | Immatics Biotechnologies Gmbh | Transficirane t ćelije i t-ćelijski receptori za upotrebu u imunoterapiji protiv malignih tumora |
| GB201604494D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| US10357550B2 (en) | 2016-04-06 | 2019-07-23 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| TW202304970A (zh) | 2016-08-26 | 2023-02-01 | 德商英麥提克生物技術股份有限公司 | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 |
| AU2018298422B2 (en) | 2017-07-04 | 2023-04-06 | CureVac SE | Novel nucleic acid molecules |
| CN111315769A (zh) | 2017-09-06 | 2020-06-19 | 加州理工学院 | 信号传导和抗原呈递双功能受体(sabr) |
| US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| JP2022096002A (ja) | 2019-04-25 | 2022-06-29 | 三洋化成工業株式会社 | アルカリ電池用ゲル化剤及びアルカリ電池 |
| CA3154655A1 (en) | 2019-09-24 | 2021-04-01 | Universite Catholique De Louvain | Modified vesicular stomatitis virus glycoprotein and uses thereof for the treatment of brain tumors |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
-
2016
- 2016-03-16 GB GBGB1604490.1A patent/GB201604490D0/en not_active Ceased
-
2017
- 2017-03-14 CN CN201780017758.8A patent/CN108883165A/zh active Pending
- 2017-03-14 AU AU2017234174A patent/AU2017234174B2/en not_active Ceased
- 2017-03-14 JP JP2018548713A patent/JP2019515653A/ja active Pending
- 2017-03-14 US US15/458,893 patent/US10512679B2/en active Active
- 2017-03-14 WO PCT/EP2017/055973 patent/WO2017157928A1/en not_active Ceased
- 2017-03-14 KR KR1020187029680A patent/KR20180127642A/ko not_active Ceased
- 2017-03-14 EP EP17710882.6A patent/EP3429617A1/en active Pending
- 2017-03-14 MX MX2018011220A patent/MX2018011220A/es unknown
- 2017-03-14 KR KR1020237009287A patent/KR20230042408A/ko not_active Ceased
- 2017-03-14 BR BR112018068489-9A patent/BR112018068489A2/pt unknown
- 2017-03-14 CA CA3017652A patent/CA3017652A1/en active Pending
-
2018
- 2018-09-15 IL IL261786A patent/IL261786A/en unknown
- 2018-09-21 US US16/138,655 patent/US10383931B2/en active Active
-
2019
- 2019-11-06 US US16/675,537 patent/US20200061171A1/en not_active Abandoned
-
2021
- 2021-12-08 AU AU2021282458A patent/AU2021282458B2/en not_active Ceased
-
2022
- 2022-06-14 JP JP2022096002A patent/JP2022130472A/ja active Pending
- 2022-08-17 US US17/820,432 patent/US12466878B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515653A5 (OSRAM) | ||
| TWI822726B (zh) | Ｎｙｅｓｏ ｔ細胞受體 | |
| JP2019516663A5 (OSRAM) | ||
| JP2021101700A5 (OSRAM) | ||
| JP2020182458A5 (OSRAM) | ||
| JP2020191862A5 (OSRAM) | ||
| JP6639233B2 (ja) | Ｍａｇｅ−ａ１を認識する高結合活性結合分子 | |
| JP2020516681A5 (OSRAM) | ||
| JP2019536426A5 (OSRAM) | ||
| JP2024041841A5 (OSRAM) | ||
| JP2019502360A5 (OSRAM) | ||
| JP2019513005A5 (OSRAM) | ||
| KR20200019211A (ko) | T 세포 수용체 | |
| JP2020506690A5 (OSRAM) | ||
| JP2018529320A5 (OSRAM) | ||
| JP2011520436A5 (OSRAM) | ||
| JP2018510628A5 (OSRAM) | ||
| JP2019511214A5 (OSRAM) | ||
| CN110022893B (zh) | 用于癌症疗法的免疫原性化合物 | |
| JP2019520038A5 (OSRAM) | ||
| FI3388075T3 (fi) | Uusia peptidejä ja peptidien yhdistelmiä käytettäviksi immunoterapiaan erilaisia syöpiä vastaan | |
| JP2021501567A (ja) | Ｙ１８２ｔ突然変異を有するｔ細胞−抗原カプラおよびその方法ならびに使用 | |
| JP2023522799A (ja) | 特異的結合性分子 | |
| JP2022095667A (ja) | Ｎｙ－ｅｓｏに対する高親和力のｔｃｒ | |
| JP2020530759A5 (OSRAM) |